Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)

Covid-19 roundup: Pfiz­er ex­pands in­to France; Omi­cron-spe­cif­ic ver­sion of Mod­er­na's boost­er com­ing soon 

As the hype sur­round­ing Pfiz­er’s an­tivi­ral Covid-19 pill swirls, the phar­ma an­nounced that it will build a pro­duc­tion fa­cil­i­ty in France to make the drug as a part of a five-year in­vest­ment.

Pfiz­er will team up with No­vasep to in­stall equip­ment and ini­ti­ate tech trans­fer and on-site de­vel­op­ment at No­vasep’s Mourenx fa­cil­i­ty. The move is a part of a $594 mil­lion in­vest­ment in France.

“We are of course proud to con­tribute to the man­u­fac­tur­ing of this med­i­cine which has shown in clin­i­cal tri­als to have a pos­i­tive im­pact on hos­pi­tal­iza­tion among at-risk Covid-19 pa­tients,” No­vasep’s CEO Michel Spag­nol said in a state­ment. “This con­tract al­so val­i­dates our in­vest­ment strat­e­gy for sev­er­al years and our fo­cus on small mol­e­cules.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.